Gyre Therapeutics (GYRE) to Release Earnings on Thursday

Gyre Therapeutics (NASDAQ:GYRE) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Gyre Therapeutics to post earnings of ($0.06) per share and revenue of $31.6070 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. On average, analysts expect Gyre Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Gyre Therapeutics Stock Performance

Shares of NASDAQ:GYRE traded down $0.04 during midday trading on Tuesday, hitting $7.88. The company’s stock had a trading volume of 8,540 shares, compared to its average volume of 88,749. The stock has a market capitalization of $764.41 million, a price-to-earnings ratio of 791.29 and a beta of 2.04. The stock’s 50 day simple moving average is $7.62 and its 200 day simple moving average is $7.71. Gyre Therapeutics has a fifty-two week low of $6.57 and a fifty-two week high of $11.78.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GYRE. Wall Street Zen downgraded Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Zacks Research downgraded Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Gyre Therapeutics presently has a consensus rating of “Hold” and an average price target of $17.00.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after buying an additional 1,402 shares during the period. JPMorgan Chase & Co. lifted its stake in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares during the period. Dimensional Fund Advisors LP bought a new position in Gyre Therapeutics during the fourth quarter worth about $77,000. Finally, Wells Fargo & Company MN lifted its stake in Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after purchasing an additional 7,361 shares during the period. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.